Nanjing Vazyme Biotech Co., Ltd.
SHH: 688105.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lin Cao
- Employees
- 2,867
- Headquarters
- Nanjing, China
- IPO year
- 2021
- Market cap
- CN¥8.1B
- Website
- https://www.vazyme.com
Loading 688105…
Loading profile data…Frequently asked questions about 688105
What does Nanjing Vazyme Biotech Co., Ltd. (688105.SS) do?
Nanjing Vazyme Biotech Co., Ltd., a biotechnology company, engages in the research, development, and production of enzymes, antigens, antibodies, and polymer organic materials. The company offers scientific research reagents, such as PCR clone point mutation, nucleic acid extraction, reverse transcription, qPCR, cell/protein, gene editing series...
Where does 688105.SS trade?
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) trades on the Shanghai Stock Exchange.
What sector is 688105.SS in?
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nanjing Vazyme Biotech Co., Ltd.?
Lin Cao is the chief executive officer of Nanjing Vazyme Biotech Co., Ltd. (688105.SS).
Where is Nanjing Vazyme Biotech Co., Ltd. headquartered?
Nanjing Vazyme Biotech Co., Ltd. is headquartered in China.
Does 688105.SS pay a dividend?
Yes — Nanjing Vazyme Biotech Co., Ltd. (688105.SS) paid a trailing twelve-month dividend of CNY 0.15 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688105.SS go public?
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) completed its initial public offering in 2021.